

Diego Ferone

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3070760/diego-ferone-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

260
papers

9,977
citations

54
h-index

89
g-index

283
ext. papers

11,430
ext. citations

5.1
avg. IF

5.55
L-index

#	Paper	IF	Citations
260	The effect of sodium restriction on iodine prophylaxis: a review.. <i>Journal of Endocrinological Investigation</i> , 2022 , 1	5.2	1
259	Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature.. <i>Journal of Endocrinological Investigation</i> , 2022 , 1	5.2	0
258	Inibitori dei checkpoint immunitari e patologia tiroidea. <i>L Endocrinologo</i> , 2022 , 23, 125-132	0	
257	Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. <i>Cancers</i> , 2022 , 14, 2501	6.6	2
256	Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length. <i>Pituitary</i> , 2021 , 1	4.3	0
255	PRRT: identikit of the perfect patient. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 22, 563-579	10.5	6
254	Efficacy of a Novel Second-Generation Somatostatin-Dopamine Chimera (TBR-065) in Human Medullary Thyroid Cancer: A Preclinical Study. <i>Neuroendocrinology</i> , 2021 , 111, 937-950	5.6	3
253	"Present and future of immunotherapy in Neuroendocrine Tumors". <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021 , 22, 615-636	10.5	4
252	Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST in Mediating Ligand Effects. <i>Cancers</i> , 2021 , 13,	6.6	3
251	Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective. <i>Frontiers in Endocrinology</i> , 2021 , 12, 677919	5.7	3
250	GH Replacement in the Elderly: Is It Worth It?. <i>Frontiers in Endocrinology</i> , 2021 , 12, 680579	5.7	0
249	Safety and effectiveness of Omnitrope [®] in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 327-337	5.2	1
248	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. <i>Digestive and Liver Disease</i> , 2021 , 53, 367-374	3.3	3
247	Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet). <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 989-994	5.2	6
246	Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 789-801	5.6	4
245	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. <i>European Journal of Cancer</i> , 2021 , 144, 200-214	7.5	4
244	Vitamin D and Lung Outcomes in Elderly COVID-19 Patients. <i>Nutrients</i> , 2021 , 13,	6.7	18

243	A comparative cross-sectional study on sleep quality in patients with a history of differentiated thyroid carcinoma and its correlation with quality of life. <i>Endocrine</i> , 2021 , 73, 347-357	4	1
242	Acromegaly Management in a Tertiary Referral Center After 1 Year of the Coronavirus 2019 Pandemic: A Double Challenge. <i>Endocrine Practice</i> , 2021 , 27, 856-857	3.2	2
241	Octreotide-Resistant Acromegaly: Challenges and Solutions. <i>Therapeutics and Clinical Risk Management</i> , 2020 , 16, 379-391	2.9	9
240	Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. <i>Endocrine</i> , 2020 , 69, 441-450	4.0	10
239	Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 1543-1553	5.3	7
238	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 1094-1095	8.9	6
237	Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study. <i>Oncologist</i> , 2020 , 25, 259-265	5.7	9
236	Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 2317-2324	4	
235	Emerging drugs for the treatment of acromegaly. <i>Expert Opinion on Emerging Drugs</i> , 2020 , 25, 409-417	3.7	1
234	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	14
233	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	88
232	Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients. <i>Journal of Endocrinological Investigation</i> , 2020 , 43, 389-393	5.2	0
231	Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity. <i>Pituitary</i> , 2019 , 22, 552-560	4.3	10
230	Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	13
229	Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2019 , 20, 365-381	10.5	9
228	Adult iatrogenic Cushing's syndrome induced by topical skin corticosteroid misuse. <i>Therapie</i> , 2019 , 74, 547-549	3.8	3
227	The primary role of radiological imaging in the diagnosis of rare musculoskeletal diseases. Emphasis on ultrasound. <i>Journal of Ultrasonography: Official Publication of Polish Ultrasound Society / Red Nacz Iwona SudoSzopńska</i> , 2019 , 19, 187-192	1.1	0
226	Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 83, 375-385	3.5	9

225	Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells. <i>Pituitary</i> , 2019 , 22, 89-99	4.3	13
224	Multiple endocrine neoplasia type 1: analysis of germline MEN1 mutations in the Italian multicenter MEN1 patient database. <i>Endocrine</i> , 2018 , 62, 215-233	4	14
223	Neuroendocrine Tumours: Diagnosis, Therapy and Follow-up 2018 , 203-222		
222	Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS). <i>Journal of Endocrinological Investigation</i> , 2018 , 41, 1259-1266	5.2	4
221	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2018 , 97, 59-61	7.5	14
220	Hormone receptors analysis in idiopathic progressive subglottic stenosis. <i>Laryngoscope</i> , 2018 , 128, E72-E78		11
219	Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. <i>Endocrine</i> , 2018 , 61, 533-541	4	15
218	One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients. <i>Endocrine</i> , 2017 , 55, 573-581	4	8
217	Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. <i>Endocrine</i> , 2017 , 58, 349-359	4	48
216	Long-term safety and efficacy of Omnitrope in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. <i>Journal of Endocrinological Investigation</i> , 2017 , 40, 669-678	5.2	4
215	Somatostatin receptor ligands in the treatment of acromegaly. <i>Pituitary</i> , 2017 , 20, 100-108	4.3	62
214	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2017 , 105, 245-254	5.6	69
213	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , 2017 , 176, 453-461	6.5	39
212	ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. <i>Neuroendocrinology</i> , 2017 , 105, 201-211	5.6	80
211	High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2454-2464	5.6	29
210	In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 2009-2018	5.6	31
209	Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. <i>Journal of Endocrinological Investigation</i> , 2017 , 40, 1265-1269	5.2	3
208	KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?. <i>Endocrine</i> , 2017 , 57, 494-502	4	14

207	Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. <i>Endocrine-Related Cancer</i> , 2017 , 24, 505-518	5.7	110
206	Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. <i>Endocrine</i> , 2017 , 57, 366-375	4	23
205	Acromegaly is associated with increased cancer risk: a survey in Italy. <i>Endocrine-Related Cancer</i> , 2017 , 24, 495-504	5.7	41
204	Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors. <i>Endocrine</i> , 2017 , 57, 214-219	4	59
203	Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas. <i>Molecular Neurobiology</i> , 2017 , 54, 4879-4895	6.2	38
202	Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. <i>Endocrine</i> , 2017 , 56, 633-638	4	25
201	Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?. <i>Oncotarget</i> , 2017 , 8, 41044-41063	3.3	18
200	Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center. <i>Endocrine</i> , 2016 , 51, 524-33	4	10
199	Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. <i>Endocrine</i> , 2016 , 51, 131-9	4	31
198	Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor. <i>Neuroendocrinology</i> , 2016 , 103, 452-9	5.6	42
197	T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. <i>Endocrine-Related Cancer</i> , 2016 , 23, 871-881	5.7	47
196	Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. <i>European Journal of Endocrinology</i> , 2016 , 174, 651-62	6.5	29
195	Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins. <i>Endocrine</i> , 2016 , 53, 551-7	4	6
194	ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2016 , 103, 139-43	5.6	153
193	ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2016 , 103, 119-24	5.6	258
192	Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?. <i>Endocrine</i> , 2016 , 53, 58-62	4	16
191	Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy?. <i>Pituitary</i> , 2015 , 18, 583-91	4.3	32
190	Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. <i>European Journal of Endocrinology</i> , 2015 , 172, R227-39	6.5	89

189	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 3231-44	5.6	79
188	Rare diseases in clinical endocrinology: a taxonomic classification system. <i>Journal of Endocrinological Investigation</i> , 2015 , 38, 193-259	5.2	9
187	Cortistatins and Dopastatins 2015 , 322-334		1
186	Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry. <i>Clinical Endocrinology</i> , 2015 , 83, 527-35	3.4	3
185	Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. <i>Archives of Endocrinology and Metabolism</i> , 2015 , 59, 554-8	2.2	2
184	Pituitary image: pituicytoma. <i>Pituitary</i> , 2015 , 18, 592-7	4.3	19
183	Hormone and Receptor Candidates for Target and Biotherapy of Neuroendocrine Tumors. <i>Frontiers of Hormone Research</i> , 2015 , 44, 216-38	3.5	2
182	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. <i>Annals of Oncology</i> , 2015 , 26, 1604-20	10.3	363
181	Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives. <i>Annales DjEndocrinologie</i> , 2015 , 76, 43-58	1.7	14
180	Autonomic nervous system and cardiovascular risk assessment during one year of growth hormone replacement therapy in adults with growth hormone deficiency. <i>Hormones</i> , 2015 , 14, 134-41	3.1	3
179	Managing Cushing's disease: the state of the art. <i>Endocrine</i> , 2014 , 47, 9-20	4	52
178	Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth. <i>Molecular and Cellular Endocrinology</i> , 2014 , 382, 860-70	4.4	13
177	Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. <i>Endocrine-Related Cancer</i> , 2014 , 21, 691-704	5.7	39
176	Ectopic Cushing and other paraneoplastic syndromes in thoracic neuroendocrine tumors. <i>Thoracic Surgery Clinics</i> , 2014 , 24, 277-83	3.1	16
175	Diabetes Secondary to Neuroendocrine Gastroenteropancreatic Tumors. <i>Frontiers in Diabetes</i> , 2014 , 64-76	0.6	2
174	Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System. <i>International Journal of Endocrinology</i> , 2014 , 2014, 753524	2.7	17
173	Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients. <i>European Journal of Endocrinology</i> , 2014 , 170, 247-54	6.5	13
172	Zebrafish as an innovative model for neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2014 , 21, R67-83;7		30

171	Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. <i>Drug Discovery Today</i> , 2014 , 19, 458-68	8.8	27
170	Molecular basis of pharmacological therapy in Cushing's disease. <i>Endocrine</i> , 2014 , 46, 181-98	4	27
169	The metabolic profile in active acromegaly is gender-specific. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E51-9	5.6	38
168	Le terapie combinate nell'acromegalia: pro e contro. <i>L Endocrinologo</i> , 2013 , 14, 71-78	0	
167	Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency. <i>European Journal of Endocrinology</i> , 2013 , 169, 767-72	6.5	59
166	Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly. <i>Endocrinology</i> , 2013 , 154, 4715-25	4.8	40
165	Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E66-71	5.6	99
164	Diabetic hepatosclerosis presenting with severe cholestasis. <i>Diabetes Care</i> , 2013 , 36, e206	14.6	8
163	Interactions between vitamin D and IGF-I: from physiology to clinical practice. <i>Clinical Endocrinology</i> , 2013 , 79, 457-63	3.4	59
162	Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. <i>Clinical Endocrinology</i> , 2013 , 79, 211-6	3.4	7
161	Somatostatin receptor pathophysiology in the neuroendocrine system. <i>Expert Review of Endocrinology and Metabolism</i> , 2013 , 8, 149-157	4.1	2
160	Somatostatin, somatostatin analogs and somatostatin receptor dynamics in the biology of cancer progression. <i>Current Molecular Medicine</i> , 2013 , 13, 555-71	2.5	21
159	Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. <i>Journal of Endocrinological Investigation</i> , 2013 , 36, 38-43	5.2	38
158	Pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case for. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 613-5	5.2	10
157	Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. <i>Journal of Cellular and Molecular Medicine</i> , 2012 , 16, 1563-72	5.6	37
156	Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data. <i>Pituitary</i> , 2012 , 15, 209-14	4.3	6
155	Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience. <i>Pituitary</i> , 2012 , 15, 215-21	4.3	7
154	Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins. <i>Clinical Endocrinology</i> , 2012 , 76, 407-14	3.4	39

153	Diffuse endocrine system, neuroendocrine tumors and immunity: what's new?. <i>Neuroendocrinology</i> , 2012 , 95, 267-76	5.6	40
152	Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, E165-72	5.6	37
151	Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 326-31	5.2	33
150	Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 528-34	5.2	7
149	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 817-23	5.2	48
148	Italian Society of Endocrinology Career Award Lecture: from somatostatin to somatomedin. <i>Journal of Endocrinological Investigation</i> , 2012 , 35, 869-74	5.2	
147	Identification of a novel mutation in exon 1 of androgen receptor gene in an azoospermic patient with mild androgen insensitivity syndrome: case report and literature review. <i>Fertility and Sterility</i> , 2011 , 96, 1165-9	4.8	18
146	Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma. <i>Journal of Zhejiang University: Science B</i> , 2011 , 12, 163-73	4.5	15
145	In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5. <i>Pituitary</i> , 2011 , 14, 141-7	4.3	32
144	Musculoskeletal complications of acromegaly: what radiologists should know about early manifestations. <i>Radiologia Medica</i> , 2011 , 116, 781-92	6.5	11
143	Increased mammographic breast density in acromegaly: quantitative and qualitative assessment. <i>European Journal of Endocrinology</i> , 2011 , 164, 335-40	6.5	8
142	2. Somatostatin and dopamine receptors. <i>Tumori</i> , 2010 , 96, 802-805	1.7	6
141	Somatostatin and dopamine receptor interaction in prostate and lung cancer cell lines. <i>Journal of Endocrinology</i> , 2010 , 207, 309-17	4.7	27
140	Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells. <i>Neuroendocrinology</i> , 2010 , 92 Suppl 1, 17-22	5.6	12
139	Primary empty sella: Why and when to investigate hypothalamic-pituitary function. <i>Journal of Endocrinological Investigation</i> , 2010 , 33, 343-6	5.2	29
138	Regulation of prostate cancer cell proliferation by somatostatin receptor activation. <i>Molecular and Cellular Endocrinology</i> , 2010 , 315, 254-62	4.4	19
137	High prevalence of vitamin D deficiency and its association with left ventricular dilation: an echocardiography study in elderly patients with chronic heart failure. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010 , 20, 633-40	4.5	64
136	Somatostatin and dopamine receptors. <i>Tumori</i> , 2010 , 96, 802-5	1.7	

135	The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. <i>Journal of Molecular Endocrinology</i> , 2009 , 42, 361-70	4.5	60
134	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. <i>Neuroendocrinology</i> , 2009 , 90, 209-13	5.6	51
133	Computed tomography colonography in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 218-22	5.6	12
132	Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. <i>Acta Diabetologica</i> , 2009 , 46, 85-95	3.9	95
131	Ultrasound of peripheral nerves in acromegaly: changes at 1-year follow-up. <i>Clinical Endocrinology</i> , 2009 , 71, 220-5	3.4	20
130	Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. <i>Clinical Endocrinology</i> , 2009 , 71, 237-45	3.4	51
129	Institutional experience of PTH evaluation on fine-needle washing after aspiration biopsy to locate hyperfunctioning parathyroid tissue. <i>Journal of Zhejiang University: Science B</i> , 2009 , 10, 323-30	4.5	21
128	Calcitonin assay in wash-out fluid after fine-needle aspiration biopsy in patients with a thyroid nodule and border-line value of the hormone. <i>Journal of Endocrinological Investigation</i> , 2009 , 32, 308-12	5.2	17
127	Peptide receptor therapies in neuroendocrine tumors. <i>Journal of Endocrinological Investigation</i> , 2009 , 32, 360-9	5.2	92
126	Effect of environment on growth: auxological and hormonal parameters in African and Italian children. <i>Growth Hormone and IGF Research</i> , 2009 , 19, 238-41	2	4
125	Sonographic depiction of trigger fingers in acromegaly. <i>Journal of Ultrasound in Medicine</i> , 2009 , 28, 1441-6	2.6	9
124	Somatostatin receptor expression in thymic tumors. <i>Frontiers in Bioscience - Landmark</i> , 2009 , 14, 3304-9	2.8	6
123	A unique association of clinical "persistent müllerian duct syndrome" and syringoid carcinoma of the perineal-scrotal skin: a consequence of urologic surgery?. <i>Journal of Andrology</i> , 2008 , 29, 15-9		
122	Leptin, ghrelin, and adiponectin evaluation in transsexual subjects during hormonal treatments. <i>Journal of Andrology</i> , 2008 , 29, 580-5		13
121	Chapter 8 Autoimmunity and the Pituitary Gland. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008 , 9, 83-93	0.3	
120	Sympathovagal imbalance in transsexual subjects. <i>Journal of Endocrinological Investigation</i> , 2008 , 31, 1014-9	5.2	2
119	Usefulness of [¹¹¹ In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. <i>Journal of Endocrinological Investigation</i> , 2008 , 31, 352-9	5.2	3
118	Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population. <i>Journal of Endocrinological Investigation</i> , 2008 , 31, 445-9	5.2	36

117	Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. <i>Neuroendocrinology</i> , 2008 , 87, 31-9	5.6	90
116	The pathology of the ulnar nerve in acromegaly. <i>European Journal of Endocrinology</i> , 2008 , 159, 369-73	6.5	19
115	Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. <i>Clinical Cancer Research</i> , 2008 , 14, 5022-32	12.9	78
114	Ultrasound measurement of median and ulnar nerve cross-sectional area in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 905-9	5.6	49
113	Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases. <i>Kidney International</i> , 2008 , 74, 937-45	9.9	24
112	Correlation of in vitro and in vivo somatotrophic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 1412-7	5.6	96
111	Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. <i>Pituitary</i> , 2008 , 11, 93-102	4.3	44
110	Metabolic and cardiovascular risk in patients with a history of differentiated thyroid carcinoma: A case-controlled cohort study. <i>Thyroid Research</i> , 2008 , 1, 2	2.4	9
109	Replacement therapy and cardiovascular diseases. <i>Journal of Endocrinological Investigation</i> , 2008 , 31, 85-90	5.2	6
108	Pegvisomant in acromegaly: why, when, how. <i>Journal of Endocrinological Investigation</i> , 2007 , 30, 693-9	5.2	31
107	Somatostatin receptor scintigraphy in thoracic diseases. <i>Journal of Endocrinological Investigation</i> , 2007 , 30, 889-902	5.2	9
106	Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study. <i>Metabolism: Clinical and Experimental</i> , 2007 , 56, 699-707	12.7	6
105	Novel insights in dopamine receptor physiology. <i>European Journal of Endocrinology</i> , 2007 , 156 Suppl 1, S13-S21	6.5	90
104	The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 3854-60	5.6	47
103	Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 1592-9	5.6	69
102	Evidence of prolonged orocecal transit time and small intestinal bacterial overgrowth in acromegalic patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 2119-24	5.6	31
101	Dopamine receptor expression and function in corticotroph ectopic tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 65-9	5.6	58
100	Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas. <i>European Journal of Endocrinology</i> , 2007 , 156 Suppl 1, S37-S43	6.5	18

99	Novel chimeric somatostatin analogs: facts and perspectives. <i>European Journal of Endocrinology</i> , 2007 , 156 Suppl 1, S23-S28	6.5	30
98	Well-differentiated pancreatic tumor/carcinoma: insulinoma. <i>Neuroendocrinology</i> , 2006 , 84, 183-8	5.6	191
97	Sympathovagal imbalance in acromegalic patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 115-20	5.6	23
96	Partial visual recovery from radiation-induced optic neuropathy after hyperbaric oxygen therapy in a patient with Cushing disease. <i>European Journal of Endocrinology</i> , 2006 , 154, 813-8	6.5	33
95	Lack of Somatostatin Analogs Effectiveness in Gonadotropin-Secreting Pituitary Adenomas 2006 , 16, 208-213		1
94	Neuroendocrine-immune interactions: the role of cortistatin/somatostatin system. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1069, 129-44	6.5	38
93	Initial staging of lymphoma with octreotide and other receptor imaging agents. <i>Seminars in Nuclear Medicine</i> , 2005 , 35, 176-85	5.4	21
92	Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR. <i>Journal of Endocrinological Investigation</i> , 2005 , 28, 166-9	5.2	10
91	Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients. <i>Clinical Endocrinology</i> , 2005 , 63, 294-7	3.4	5
90	Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005 , 289, E1044-50	6	37
89	Cabergoline plus lanreotide for ectopic Cushing's syndrome. <i>New England Journal of Medicine</i> , 2005 , 352, 2457-8	59.2	68
88	Potential indications for somatostatin analogues: immune system and lymphoproliferative disorders. <i>Journal of Endocrinological Investigation</i> , 2005 , 28, 111-7	5.2	7
87	Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 4493-502	5.6	63
86	Dopamine receptor expression and function in corticotroph pituitary tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2452-62	5.6	210
85	Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. <i>Clinical Endocrinology</i> , 2004 , 61, 138-44	3.4	34
84	Cost-of-illness study in acromegalic patients in Italy. <i>Journal of Endocrinological Investigation</i> , 2004 , 27, 1034-9	5.2	42
83	Systemic complications of acromegaly: epidemiology, pathogenesis, and management. <i>Endocrine Reviews</i> , 2004 , 25, 102-52	27.2	880
82	Somatostatin receptor distribution and function in immune system. <i>Digestive and Liver Disease</i> , 2004 , 36 Suppl 1, S68-77	3.3	31

81	The role of somatostatin receptors in the medical treatment of acromegaly. <i>Digestive and Liver Disease</i> , 2004 , 36 Suppl 1, S55-9	3.3	5
80	Somatostatin Control of Immune Functions 2004 , 193-206		
79	Current diagnostic guidelines for biochemical diagnosis of acromegaly. <i>Minerva Endocrinologica</i> , 2004 , 29, 207-23	1.9	7
78	In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003 , 18, 895-902	3.9	8
77	The role of somatostatin and somatostatin analogs in the pathophysiology of the human immune system. <i>Journal of Endocrinological Investigation</i> , 2003 , 26, 94-102	5.2	2
76	The role of somatostatin analogs in the management of immunoproliferative disease. <i>Journal of Endocrinological Investigation</i> , 2003 , 26, 103-8	5.2	2
75	(99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. <i>Clinical Endocrinology</i> , 2002 , 56, 713-21	3.4	6
74	Acromegaly and immune function. <i>NeuroImmune Biology</i> , 2002 , 247-257		1
73	Lymphocyte subset pattern in acromegaly. <i>Journal of Endocrinological Investigation</i> , 2002 , 25, 125-8	5.2	19
72	Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002 , 283, E1056-66	6	50
71	In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. <i>Clinical Endocrinology</i> , 2001 , 54, 469-77	3.4	22
70	Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. <i>Clinical Endocrinology</i> , 2001 , 54, 97-106	3.4	6
69	Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. <i>Clinical Endocrinology</i> , 2001 , 54, 515-24	3.4	84
68	Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 2779-86	5.6	213
67	Neuroendocrine aspects of immunolymphoproliferative diseases. <i>Annals of Oncology</i> , 2001 , 12 Suppl 2, S125-30	10.3	8
66	Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001 , 86, 1551-7	5.6	94
65	In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features. <i>Journal of Endocrinological Investigation</i> , 2001 , 24, 522-8	5.2	19
64	. <i>Annals of Oncology</i> , 2001 , 12, 125-130	10.3	6

63	Physiological and pathophysiological role of somatostatin receptors in the human thymus. <i>European Journal of Endocrinology</i> , 2000 , 143 Suppl 1, S27-34	6.5	24
62	Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease. <i>European Journal of Endocrinology</i> , 2000 , 143 Suppl 1, S35-42	6.5	5
61	Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. <i>Clinical Endocrinology</i> , 2000 , 52, 437-45	3.4	40
60	Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. <i>Clinical Endocrinology</i> , 2000 , 53, 13-9	3.4	43
59	Age-related decrease of somatostatin receptor number in the normal human thymus. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2000 , 279, E791-8	6	20
58	Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 1719-26	5.6	51
57	Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 193-9	5.6	137
56	Cardiac effect of thyrotoxicosis in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 1426-32	5.6	15
55	Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 3754-61	5.6	34
54	Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 4099-103	5.6	89
53	Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 3132-40	5.6	85
52	Pharmacotherapy or surgery as primary treatment for acromegaly?. <i>Drugs and Aging</i> , 2000 , 17, 81-92	4.7	26
51	Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1518-23	5.6	61
50	Endoscopic endonasal transsphenoidal approach: an additional reason in support of surgery in the management of pituitary lesions. <i>Skull Base</i> , 1999 , 9, 109-17		77
49	Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 2664-72	5.6	291
48	In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. <i>Endocrinology</i> , 1999 , 140, 373-80	4.8	82
47	Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 17-23	5.6	101
46	Effect of growth hormone (GH) and insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 1986-91	5.6	58

45	Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study. <i>Clinical Endocrinology</i> , 1999 , 51, 159-64	3.4	13
44	Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. <i>Clinical Endocrinology</i> , 1999 , 51, 611-8	3.4	51
43	Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. <i>Pituitary</i> , 1999 , 1, 115-20	4.3	69
42	The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas. <i>Journal of Endocrinological Investigation</i> , 1999 , 22, 176-83	5.2	35
41	Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. <i>Journal of Endocrinological Investigation</i> , 1999 , 22, 40-7	5.2	64
40	Somatostatin receptors in the thymus. <i>Annals of Medicine</i> , 1999 , 31 Suppl 2, 28-33	1.5	3
39	Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushing's disease. <i>Clinical Endocrinology</i> , 1998 , 49, 77-84	3.4	12
38	Prostatic Hyperplasia: An Unknown Feature of Acromegaly. <i>Journal of Urology</i> , 1998 , 160, 1583-1584	2.5	
37	Height, weight, height velocity of primary school population sample in Campania region. <i>Journal of Endocrinological Investigation</i> , 1998 , 21, 142-7	5.2	5
36	Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing's disease before and after corticotropin-releasing hormone administration. <i>Journal of Endocrinological Investigation</i> , 1998 , 21, 257-62	5.2	3
35	Effect of surgery and radiotherapy on visual and endocrine function in nonfunctioning pituitary adenomas. <i>Journal of Endocrinological Investigation</i> , 1998 , 21, 284-90	5.2	67
34	Bone mineral density and circulating cytokines in patients with acromegaly. <i>Journal of Endocrinological Investigation</i> , 1998 , 21, 688-93	5.2	29
33	Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 248-52	5.6	32
32	Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 3790-4	5.6	32
31	Reversibility of joint thickening in acromegalic patients: an ultrasonography study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 2121-5	5.6	60
30	Prostatic hyperplasia: an unknown feature of acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 775-9	5.6	86
29	Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. <i>European Journal of Endocrinology</i> , 1998 , 138, 286-93	6.5	86
28	Effect of different dopaminergic agents in the treatment of acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 518-23	5.6	121

27	Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 876-83	5.6	189
26	Effect of octreotide pretreatment on surgical outcome in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 3308-14	5.6	184
25	Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997 , 82, 2777-81	5.6	113
24	Effect of growth hormone on cardiac function. <i>Hormone Research</i> , 1997 , 48 Suppl 4, 38-42		46
23	Failure of long-term therapy with sodium valproate in Cushing's disease. <i>Journal of Endocrinological Investigation</i> , 1997 , 20, 387-92	5.2	25
22	Different sensitivity to sodium valproate in healthy, non-tumoral and tumoral hyperprolactinemic subjects. <i>Journal of Endocrinological Investigation</i> , 1997 , 20, 513-8	5.2	3
21	Fixity of vocal cords and laryngocele in acromegaly. <i>Journal of Endocrinological Investigation</i> , 1997 , 20, 672-4	5.2	9
20	Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. <i>Clinical Endocrinology</i> , 1997 , 47, 23-8	3.4	77
19	Acute administration of hexarelin stimulates GH secretion during day and night in normal men. <i>Clinical Endocrinology</i> , 1997 , 46, 275-9	3.4	2
18	Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. <i>Journal of Endocrinology</i> , 1997 , 155 Suppl 1, S33-7; discussion S39	4.7	19
17	Prediction of efficacy of octreotide therapy in patients with acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996 , 81, 2356-62	5.6	112
16	Cardiovascular aspects in acromegaly: effects of treatment. <i>Metabolism: Clinical and Experimental</i> , 1996 , 45, 57-60	12.7	32
15	Tumor necrosis factor-alpha increases after corticotropin-releasing hormone administration in Cushing's disease. In vivo and in vitro studies. <i>Neuroendocrinology</i> , 1996 , 64, 393-7	5.6	8
14	Vasopressin levels in Cushing's disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing's disease. <i>Clinical Endocrinology</i> , 1996 , 45, 157-66	3.4	10
13	Corticotropin-releasing hormone administration increases alpha-melanocyte-stimulating hormone levels in the inferior petrosal sinuses in a subset of patients with Cushing's disease. <i>Hormone Research</i> , 1996 , 46, 26-32		4
12	Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. <i>Hormone Research</i> , 1995 , 44, 222-8		19
11	Impaired luteinizing hormone responsiveness to gonadotropin-releasing hormone in the inferior petrosal sinuses of hyperprolactinemic patients. <i>Gynecological Endocrinology</i> , 1995 , 9, 15-21	2.4	7
10	Technetium-99m pentavalent dimercaptosuccinic acid imaging in patients with pituitary adenomas. <i>European Journal of Endocrinology</i> , 1995 , 133, 38-47	6.5	9

9	CV 205-502 treatment in therapy-resistant acromegalic patients. <i>European Journal of Endocrinology</i> , 1995 , 132, 559-64	6.5	31
8	Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas. <i>European Journal of Endocrinology</i> , 1995 , 133, 189-94	6.5	7
7	Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. <i>Gynecological Endocrinology</i> , 1994 , 8, 175-81	2.4	22
6	Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies. <i>European Journal of Endocrinology</i> , 1994 , 131, 14-9	6.5	9
5	Hypothalamic-pituitary-adrenal axis in neuropsychiatric disorders. <i>Annals of the New York Academy of Sciences</i> , 1994 , 741, 263-70	6.5	8
4	Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas. <i>Hormone Research</i> , 1993 , 40, 149-55		27
3	Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1993 , 77, 790-3	5.6	92
2	Further evaluation of IGF-I responsiveness to ACTH in children affected with IGHD. <i>Hormone Research</i> , 1992 , 38, 150-3		1
1	Effect of Growth Hormone (GH) and Insulin-Like Growth Factor I on Prostate Diseases: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects		22